Evidence map›Paper›PMID 21858040›Full record

ArticlePloS one2011

Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.

Yali Chen, Adams Amantana, Shanthakumar R Tyavanagimatt, Daniela Zima, X Steven Yan, Gopi Kasi, Morgan Weeks, Melialani A Stone, William C Weimers, Peter Samuel and 11 more

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05976100 (An Open, Simple, Randomized Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years in Parallel Groups), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05976100 phase1completednot on this mapstarted 2020, after this paper: background citation

An Open, Simple, Randomized Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years in Parallel Groups

TypeinterventionalSponsorFederal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"Ran2020 to 2022Enrolled90ConditionsSmallpox, Monkeypox, Cowpox, Vaccinia Virus InfectionArmsNIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally, NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day), NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day), NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days, NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  3. Review
  4. Article
  5. Antivirals With Activity Against Mpox: A Clinically Oriented Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Review
  6. Monkeypox Virus Infections in Humans.Clinical microbiology reviews · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Yali ChenSIGA Technologies, Corvallis, Oregon, United States of America.
Adams Amantana
Shanthakumar R Tyavanagimatt
Daniela Zima
X Steven Yan
Gopi Kasi
Morgan Weeks
Melialani A Stone
William C Weimers
Peter Samuel
Ying Tan
Kevin F Jones
Daniel R Lee
Shirley S Kickner
Bradley M Saville
Martin Lauzon
Alan McIntyre
Kady M Honeychurch
Robert Jordan
Dennis E Hruby
Janet M Leeds
Siga Technologies (United States) · USCharles River Laboratories (United States) · USCanadian Nuclear Laboratories · CA

Funding

NIAID NIH HHS HHSN266200600014CNIAID NIH HHS HHSN272200800041C
6 · The paper itself

Abstract

backgroundST-246® is an antiviral, orally bioavailable small molecule in clinical development for treatment of orthopoxvirus infections. An intravenous (i.v.) formulation may be required for some hospitalized patients who are unable to take oral medication. An i.v. formulation has been evaluated in three species previously used in evaluation of both efficacy and toxicology of the oral formulation. METHODOLOGY/PRINCIPAL

findingsThe pharmacokinetics of ST-246 after i.v. infusions in mice, rabbits and nonhuman primates (NHP) were compared to those obtained after oral administration. Ten minute i.v. infusions of ST-246 at doses of 3, 10, 30, and 75 mg/kg in mice produced peak plasma concentrations ranging from 16.9 to 238 µg/mL. Elimination appeared predominately first-order and exposure dose-proportional up to 30 mg/kg. Short i.v. infusions (5 to 15 minutes) in rabbits resulted in rapid distribution followed by slower elimination. Intravenous infusions in NHP were conducted at doses of 1 to 30 mg/kg. The length of single infusions in NHP ranged from 4 to 6 hours. The pharmacokinetics and tolerability for the two highest doses were evaluated when administered as two equivalent 4 hour infusions initiated 12 hours apart. Terminal elimination half-lives in all species for oral and i.v. infusions were similar. Dose-limiting central nervous system effects were identified in all three species and appeared related to high C(max) plasma concentrations. These effects were eliminated using slower i.v. infusions. CONCLUSIONS/SIGNIFICANCE: Pharmacokinetic profiles after i.v. infusion compared to those observed after oral administration demonstrated the necessity of longer i.v. infusions to (1) mimic the plasma exposure observed after oral administration and (2) avoid C(max) associated toxicity. Shorter infusions at higher doses in NHP resulted in decreased clearance, suggesting saturated distribution or elimination. Elimination half-lives in all species were similar between oral and i.v. administration. The administration of ST-246 was well tolerated as a slow i.v. infusion.

Indexed as

Administration, OralAnimalsAntiviral AgentsArea Under CurveBenzamidesBiological AvailabilityDose-Response Relationship, DrugDrug Evaluation, PreclinicalFemaleHumansInfusions, IntravenousIsoindolesMacaca fascicularisMaleMetabolic Clearance RateMiceAntiviral AgentsBenzamidesIsoindolesPhthalimidestecovirimat

Identifiers

PMID21858040
PMCPMC3156126
OpenAlexW1985149546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.